WGU D116 — ADVANCED PHARMACOLOGY
Premium Original Study Guide • Advanced Clinical Reasoning • Practice Questions • Rapid Review
Important: This is an original educational resource inspired by the public topic descriptions surrounding the referenced D116
Stuvia listing. It does not reproduce WGU assessment items, the Stuvia document, copyrighted answer keys, or purported “actual
exam” questions.
The referenced listing is a 27-page 2026/2027 exam-style resource. Public D116 materials consistently emphasize
pharmacokinetics/pharmacodynamics, drug interactions, therapeutic uses, adverse effects, medication safety, therapeutic
monitoring and prescribing across major systems. Publicly visible topic lists also emphasize cardiovascular/renal, autonomic/CNS,
transitions of care, supplements/herbals, GI/endocrine/obesity, and antimicrobial/oncology concepts.
Because pharmacology is clinical and time-sensitive, this guide teaches mechanisms and decision-making rather than presenting
its content as a substitute for current prescribing references, institutional policy, or the assigned WGU course materials.
,MASTER FRAMEWORK: THE 7 QUESTIONS
For almost any medication, ask: 1) What is the target? 2) What changes physiologically? 3) Why does that help this patient?
4) What can harm the patient? 5) What interactions matter? 6) What must be monitored? 7) What should the patient know?
PK: what the body does to the drug — absorption, distribution, metabolism, excretion. PD: what the drug does to the body —
receptors, signaling, dose-response and clinical effects.
Advanced-practice mindset: medication selection is not only about choosing a drug. Consider indication, patient-specific factors,
renal/hepatic function, pregnancy/lactation considerations, comorbidities, interactions, adherence, monitoring and shared
decision-making.
,UNIT 1 — PHARMACOKINETICS & PHARMACODYNAMICS
ADME. Absorption determines systemic entry; distribution determines movement among compartments; metabolism chemically
transforms drugs; excretion removes parent drug and/or metabolites.
Bioavailability. IV administration is effectively complete systemic delivery, whereas oral exposure can be reduced by incomplete
absorption and first-pass metabolism. Route matters when rapid or predictable exposure is required.
Half-life & steady state. With first-order elimination, a constant fraction is removed per unit time. Repeated dosing approaches
steady state over several half-lives. A loading dose can reach a target concentration more quickly; a maintenance regimen primarily
replaces ongoing elimination.
CYP interactions. Enzyme inhibition can increase concentrations of susceptible substrates; induction can decrease them. Always
identify the specific drug pair rather than assuming every CYP interaction behaves identically.
Pharmacodynamics. Potency is the amount needed for an effect; efficacy is the maximum effect. Full agonists, partial agonists,
antagonists and inverse agonists differ in receptor behavior.
, UNIT 2 — AUTONOMIC & CNS PHARMACOLOGY
High-yield receptor map: α1 often increases vascular tone; β1 increases cardiac rate/contractility; β2 promotes bronchodilation; M3
commonly increases glandular secretion and smooth-muscle activity. Clinical questions often test the physiologic consequence
rather than the receptor name alone.
Cholinergic excess: think secretions, bronchoconstriction, bradycardia and increased GI activity. Adrenergic excess: think
tachycardia, tremor, vasoconstriction and metabolic stimulation.
Psychopharmacology: SSRIs increase serotonergic signaling; MAOIs require attention to interacting drugs and
tyramine-containing foods; antipsychotics require monitoring for movement disorders, metabolic effects and rare severe reactions;
lithium requires attention to hydration, renal function and drug interactions.
Neurologic therapy: levodopa/carbidopa increases dopamine availability in Parkinson disease; cholinesterase inhibitors may
support cholinergic signaling in Alzheimer disease and myasthenia gravis therapy uses cholinergic enhancement to improve
neuromuscular transmission.
Premium Original Study Guide • Advanced Clinical Reasoning • Practice Questions • Rapid Review
Important: This is an original educational resource inspired by the public topic descriptions surrounding the referenced D116
Stuvia listing. It does not reproduce WGU assessment items, the Stuvia document, copyrighted answer keys, or purported “actual
exam” questions.
The referenced listing is a 27-page 2026/2027 exam-style resource. Public D116 materials consistently emphasize
pharmacokinetics/pharmacodynamics, drug interactions, therapeutic uses, adverse effects, medication safety, therapeutic
monitoring and prescribing across major systems. Publicly visible topic lists also emphasize cardiovascular/renal, autonomic/CNS,
transitions of care, supplements/herbals, GI/endocrine/obesity, and antimicrobial/oncology concepts.
Because pharmacology is clinical and time-sensitive, this guide teaches mechanisms and decision-making rather than presenting
its content as a substitute for current prescribing references, institutional policy, or the assigned WGU course materials.
,MASTER FRAMEWORK: THE 7 QUESTIONS
For almost any medication, ask: 1) What is the target? 2) What changes physiologically? 3) Why does that help this patient?
4) What can harm the patient? 5) What interactions matter? 6) What must be monitored? 7) What should the patient know?
PK: what the body does to the drug — absorption, distribution, metabolism, excretion. PD: what the drug does to the body —
receptors, signaling, dose-response and clinical effects.
Advanced-practice mindset: medication selection is not only about choosing a drug. Consider indication, patient-specific factors,
renal/hepatic function, pregnancy/lactation considerations, comorbidities, interactions, adherence, monitoring and shared
decision-making.
,UNIT 1 — PHARMACOKINETICS & PHARMACODYNAMICS
ADME. Absorption determines systemic entry; distribution determines movement among compartments; metabolism chemically
transforms drugs; excretion removes parent drug and/or metabolites.
Bioavailability. IV administration is effectively complete systemic delivery, whereas oral exposure can be reduced by incomplete
absorption and first-pass metabolism. Route matters when rapid or predictable exposure is required.
Half-life & steady state. With first-order elimination, a constant fraction is removed per unit time. Repeated dosing approaches
steady state over several half-lives. A loading dose can reach a target concentration more quickly; a maintenance regimen primarily
replaces ongoing elimination.
CYP interactions. Enzyme inhibition can increase concentrations of susceptible substrates; induction can decrease them. Always
identify the specific drug pair rather than assuming every CYP interaction behaves identically.
Pharmacodynamics. Potency is the amount needed for an effect; efficacy is the maximum effect. Full agonists, partial agonists,
antagonists and inverse agonists differ in receptor behavior.
, UNIT 2 — AUTONOMIC & CNS PHARMACOLOGY
High-yield receptor map: α1 often increases vascular tone; β1 increases cardiac rate/contractility; β2 promotes bronchodilation; M3
commonly increases glandular secretion and smooth-muscle activity. Clinical questions often test the physiologic consequence
rather than the receptor name alone.
Cholinergic excess: think secretions, bronchoconstriction, bradycardia and increased GI activity. Adrenergic excess: think
tachycardia, tremor, vasoconstriction and metabolic stimulation.
Psychopharmacology: SSRIs increase serotonergic signaling; MAOIs require attention to interacting drugs and
tyramine-containing foods; antipsychotics require monitoring for movement disorders, metabolic effects and rare severe reactions;
lithium requires attention to hydration, renal function and drug interactions.
Neurologic therapy: levodopa/carbidopa increases dopamine availability in Parkinson disease; cholinesterase inhibitors may
support cholinergic signaling in Alzheimer disease and myasthenia gravis therapy uses cholinergic enhancement to improve
neuromuscular transmission.
